LICENSE AGREEMENTS (Details) - USD ($) $ in Millions |
6 Months Ended | |
|---|---|---|
Aug. 04, 2017 |
Dec. 31, 2021 |
|
| ActiveSite Pharmaceuticals, Inc. [Member] | ||
| License Agreements | ||
| Maximum Amount of Milestone Events | $ 46.5 | |
| First milestone payment due after completion of the preclinical work | $ 1.0 | |
| Xoma | ||
| License Agreements | ||
| Milestone closing payment | $ 37.0 | |
| Phase 2 Clinical Trial RZ402 | ||
| License Agreements | ||
| Milestone closing payment | 3.0 | |
| Phase 2 Clinical Trial RZ358 | ||
| License Agreements | ||
| Milestone closing payment | $ 2.0 |
| X | ||||||||||
- Definition Represents the first milestone payment due after completion of the preclinical work. No definition available.
|
| X | ||||||||||
- Definition The maximum amount of milestone event which need to occur for making specific range of milestone payment. No definition available.
|
| X | ||||||||||
- Definition Amount of milestone payment made during the period. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|